TEVA PHARM Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA PHARM, and when can generic versions of TEVA PHARM drugs launch?
TEVA PHARM has three hundred and twenty approved drugs.
There are thirty-two US patents protecting TEVA PHARM drugs. There are forty-four tentative approvals on TEVA PHARM drugs.
There are four hundred and thirty-six patent family members on TEVA PHARM drugs in thirty-six countries and nine hundred and fifteen supplementary protection certificates in eighteen countries.
Summary for TEVA PHARM
International Patents: | 436 |
US Patents: | 32 |
Tradenames: | 268 |
Ingredients: | 260 |
NDAs: | 320 |
Patent Litigation for TEVA PHARM: | See patent lawsuits for TEVA PHARM |
PTAB Cases with TEVA PHARM as petitioner: | See PTAB cases with TEVA PHARM as petitioner |
Drugs and US Patents for TEVA PHARM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Pharms | ROCURONIUM BROMIDE | rocuronium bromide | INJECTABLE;INJECTION | 078717-001 | Nov 26, 2008 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Teva Pharms Usa | EPINEPHRINE (AUTOINJECTOR) | epinephrine | INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS | 090589-002 | Aug 16, 2018 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Teva Pharms Usa | OLMESARTAN MEDOXOMIL | olmesartan medoxomil | TABLET;ORAL | 091079-003 | Apr 24, 2017 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Teva Pharm | ARMONAIR DIGIHALER | fluticasone propionate | POWDER;INHALATION | 208798-005 | Feb 20, 2020 | RX | Yes | No | 10,124,131*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Teva Pharms | DEXMETHYLPHENIDATE HYDROCHLORIDE | dexmethylphenidate hydrochloride | TABLET;ORAL | 077107-003 | Jan 29, 2007 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TEVA PHARM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-002 | Feb 1, 2007 | 7,820,203 | ⤷ Try a Trial |
Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-002 | Feb 12, 2002 | 6,054,430 | ⤷ Try a Trial |
Teva Pharm | AIRDUO DIGIHALER | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-004 | Jul 12, 2019 | 6,748,947 | ⤷ Try a Trial |
Teva Pharm | AIRDUO DIGIHALER | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-004 | Jul 12, 2019 | 6,871,646 | ⤷ Try a Trial |
Teva Pharm | ARMONAIR DIGIHALER | fluticasone propionate | POWDER;INHALATION | 208798-006 | Feb 20, 2020 | 6,871,646 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA PHARM drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Capsule | 15 mg and 30 mg | ➤ Subscribe | 2008-08-11 |
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-02-26 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | for Injection | 3.5 mg/vial | ➤ Subscribe | 2016-10-26 |
➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-01-29 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
Premature patent expirations for TEVA PHARM
Expiration due to failure to pay maintenance fee
Patent Number | Expiration Date |
---|---|
⤷ Try a Trial | ⤷ Try a Trial |
International Patents for TEVA PHARM Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 114177442 | ⤷ Try a Trial |
Israel | 286577 | ⤷ Try a Trial |
South Korea | 20130103823 | ⤷ Try a Trial |
Turkey | 201901080 | ⤷ Try a Trial |
European Patent Office | 3247331 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for TEVA PHARM Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0454511 | C980039 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: IRBESARTAN, DESGEWENST IN DE VORM VAN EEN ZOUT EN/OF EEN HYDRAA T; REGISTRATION NO/DATE: EU/1/97/046/001 - 009 19970827 |
1411900 | 18/2011 | Austria | ⤷ Try a Trial | PRODUCT NAME: NAPROXEN UND ESOMEPRAZOL SOWIE DEREN PHARMAZEUTISCH ANNEHMBARE SALZE; NAT. REGISTRATION NO/DATE: 1-29937 20110105; FIRST REGISTRATION: GB PL 17901/0263-0001 20101105 |
3143995 | C03143995/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: EVEROLIMUS; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 59174 14.11.2016 |
1506211 | CA 2014 00037 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116 |
1663240 | PA2015038 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: RILPIVIRINUM + TENOFOVIRUM DISOPROXILUM; REGISTRATION NO/DATE: EU/1/11/737/001, 2011 11 28, EU/1/11/737/002 20111128 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.